The market is about right about the acquisition. I expect earnings to improve, but integration payments will limit debt repayment and dividend flexibility. My twelve-month target is $110.63.
Key points
- $110.63 a share is my twelve-month target; hold.
- $7.38 a share is my 2027 combined adjusted earnings forecast.
- $2.4 billion of estimated 2027 free cash falls short of unchanged dividends.
The call
The market is about right, not demanding a merger miracle. At 15 times earnings, today's price requires $6.94 a share in 2027. With modest sales growth, that means roughly a 19% operating margin after the acquisition. The bigger question is whether accounting profits become cash available to shareholders.
Kenvue sells more, but two divisions earn lessKenvue August 6, 2026 release; segment adjusted operating income, $ millions; definitions differ from GAAP.
I expect better earnings, but limited room for a higher valuation. Kenvue's latest sales recovery masks falling profit in two divisions. My forecast includes only $250 million of merger savings in 2027. Closing and the first combined outlook should clarify delivery, but integration bills restrain debt repayment. Persistent underperformance against the market argues against anticipating a rapid recovery.
Valuation
| Driver | My estimate |
|---|
| 2027 combined sales | $32.5 billion |
| 2027 adjusted operating profit | $6.7 billion |
| 2027 adjusted earnings per share | $7.38 |
| Base earnings multiple | 14 times |
| Trusted-brand premium | 1 times |
| Twelve-month target | $110.63 |
Earnings assume $950 million of net interest, a 25% tax rate and 617 million diluted shares, including acquisition issuance; adjusted earnings exclude integration charges and acquired-brand amortization. The brand premium recognizes repeat purchases, but disappears if market share erodes. I estimate $2.4 billion of cash after capital spending and $1.25 billion of integration payments, versus $3.2 billion of unchanged annual dividends; downside near $85 balances an optimistic outcome near $141.
Risks
- Faster savings could make this hold too cautious; watch combined-company margins and cash generation.
- Weak consumers and higher material costs could squeeze profits; watch pricing, volumes and China sales.
- Acquired litigation could consume cash; watch acetaminophen proceedings and overseas talc claims.
What would change my mind
Combined-company guidance showing recurring cash comfortably covering dividends and integration payments without additional borrowing would justify a higher target.